Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Study of Chemotherapy and Surgery for Liver Cancer in Children and Young Adults

Recruiting
30 years or below
All
Phase N/A
1 Location

Brief description of study.

This trial studies how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery.

Detailed description of study

The purpose of this study is to reduce therapy associated toxicity for patients with non-metastatic hepatoblastoma (HB) and hepatocellular carcinoma (HCC) without adversely affecting long term outcomes; and to determine the event-free survival (EFS) in patients with HB whose tumor is completely resected at diagnosis and either receive no adjuvant chemotherapy (completely resected well differentiated fetal histology HB) or 2 cycles of standard dose cisplatin monotherapy (completely resected non-well differentiated fetal histology HB ? 100 mg/m^2/cycle given 3 weeks apart).
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: hepatoblastoma,liver cancer
  • Age: 30 years or below
  • Gender: All

Inclusion Criteria
Patients must be newly diagnosed with hepatoblastoma or hepatocellular carcinoma
Exclusion Criteria
Prior chemotherapy or tumor directed therapy (i.e. radiation therapy, biologic agents, local therapy (embolization, radiofrequency ablation, and laser); therefore, patients with a pre-disposition syndrome who have a prior malignancy are not eligible
Patients who are currently receiving another investigational drug
Patients who are currently receiving other anticancer agents
Patients with uncontrolled infection
Patients who previously received a solid organ transplant
This criteria apply ONLY to patients who will receive chemotherapy (all groups other than Group E1):
Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Lactating females who plan to breastfeed their infants
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Note for Group F: patients of childbearing potential should use effective birth control during treatment with sorafenib and for at least 2 weeks after stopping treatment

Updated on 19 Feb 2024. Study ID: PHO-COG-AHEP1531

This study investigates how well chemotherapy works in treating children and young adults with liver cancer, specifically hepatoblastoma and hepatocellular carcinoma, after surgery. Hepatoblastoma is a rare liver cancer that occurs in children, while hepatocellular carcinoma is a more common type of liver cancer that can affect young adults. The purpose of this study is to reduce the side effects of therapy for patients with non-metastatic liver cancer without affecting their long-term health outcomes.

Participants in this study will undergo surgery to remove the liver tumor. Depending on the type of cancer cells found in the tumor, some patients may receive no additional chemotherapy, while others may receive two cycles of a chemotherapy drug called cisplatin. Chemotherapy uses powerful drugs to kill cancer cells and is often given in cycles to allow the body to recover between treatments.

  • Who can participate: Children and young adults newly diagnosed with hepatoblastoma or hepatocellular carcinoma can participate. Patients must not have received prior chemotherapy or any tumor-directed therapy.
  • Study details: Participants will undergo surgery to remove the liver tumor. Some may receive cisplatin chemotherapy, which is given in cycles.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here